Investigating the role of a protein in kidney damage related to nephrotic syndrome
Official title: The Role of Proprotein-convertase-subtilisin/Kexin-type 9 in Kidney Damage in Nephrotic Syndrom
Run by Kolding Sygehus · NCT06373913 · Data updated 2026-11-12
This study is trying to see if a protein called PCSK9 is linked to kidney damage and high cholesterol in people with nephrotic syndrome.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 75 (estimated) |
| Sponsor | Kolding Sygehus Academic / other |
| Locations | 1 site (Kolding) |
| Status | Recruiting |
| Started | June 1, 2023 |
| Main results expected | July 30, 2027 |
| Study ends | July 30, 2028 |
| Registry record updated | September 9, 2025 |
| Trial ID | NCT06373913 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older who are admitted to the Medical Department or Medical Emergency Department with nephrotic syndrome.
✕Probably not a fit
Patients who are currently receiving treatment with PCSK9 inhibitors or have conditions that limit their ability to participate may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study aims to explore the role of proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with nephrotic syndrome (NS) and associated hyperlipidemia. It will compare plasma levels of PCSK9 between patients with NS and kidney-healthy controls, as well as assess the correlation between PCSK9 levels and the degree of proteinuria. Additionally, kidney tissue biopsies will be analyzed to evaluate PCSK9 expression in patients with NS. The study seeks to understand how PCSK9 contributes to hyperlipidemia and kidney damage in this patient population.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of hyperlipidemia in patients with nephrotic syndrome, potentially reducing morbidity and mortality.
How similar studies have gone: While the role of PCSK9 in nephrotic syndrome is being explored, this specific investigation is novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years old * Patients admitted to the Medical Department and/or the Medical Emergency Department, Kolding Sygehus. Exclusion Criteria: * Refusal to give informed consent * Treatment with PCSK9 inhibitors * Any acute or chronic condition that would limit the ability of the patient to participate in the study * Control group: proteinuria
Where it's running
-
Kolding Sygehus, Lillebælt Hospital
Kolding, Denmark Recruiting
Study contacts
- Study coordinator: Rikke Z Langkilde, MD, phd
- Email: rikke.zachar.langkilde@rsyd.dk
- Phone: 004576362554
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Smartphone app to help follow the 2024 KDIGO chronic kidney disease guidelines
This project will test whether a smartphone app helps young adults (ages 16–29) with chronic kidney disease follow the 2024 KDIGO guideline recommendations.
-
SGLT2 inhibitors added to standard care in adult primary nephrotic syndrome
This trial tests whether adding dapagliflozin or empagliflozin to standard treatment helps reduce protein in urine for adults with primary nephrotic syndrome.
-
Atacicept for multiple autoimmune glomerular diseases
This will test whether weekly injections of atacicept can lower protein in the urine and help preserve kidney function in people aged 10 and older with IgA nephropathy, primary membranous nephropathy, or nephrotic syndromes such as MCD and FSGS.
-
WE CARE social needs screening and referral for families in primary care
This project will test whether using the WE CARE social needs screening and referral program with an antiracist approach in family medicine can help reduce chronic conditions like diabetes, high blood pressure, depression, high cholesterol, and pediatric asthma for minoritized patients.
-
Multitarget approach for primary podocytopathies
This project will test whether a lab cell culture can find a factor in the blood that causes proteinuria in people with primary podocytopathies and whether a combined therapy can block that factor in vitro.
-
Follow-up on Rituximab treatment for children's nephrotic syndrome
This study looks at how well rituximab works and its safety for children with hard-to-treat nephrotic syndrome by reviewing their past treatment data.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.